IL-1β mRNA levels (Fig. 5A) in CKD-DTNB treated mice was reduced by 1.4-fold as compared to CKD mice (37.3 and 51.9 fold of C respectively, p < 0.05). This evidence concerns the gene IL1B and chronic kidney disease.